Search Result

Results for "

Liver Metabolism

" in MedChemExpress (MCE) Product Catalog:

By Targets:	LXR (4) Mitochondrial Metabolism (5) 17β-HSD (2) 5 alpha Reductase (1) Acetyl-CoA Carboxylase (5) ACSL Family (1) Akt (5) Aldehyde Dehydrogenase (ALDH) (1) Amino Acid Derivatives (1) Aminotransferases (Transaminases) (4) AMPK (6) Amylases (3) Anaplastic lymphoma kinase (ALK) (1) Angiotensin-converting Enzyme (ACE) (1) AP-1 (1) Apical Sodium-Dependent Bile Acid Transporter (1) Apoptosis (23) Arginase (2) Autophagy (15) Bacterial (3) Bcl-2 Family (10) Biochemical Assay Reagents (4) Bradykinin Receptor (1) c-Myc (1) CaMK (1) Carnitine Palmitoyltransferase (CPT) (2) Caspase (1) CaSR (2) Cholinesterase (ChE) (4) Claudin (2) Collagen (1) COX (1) Cytochrome P450 (10) Dengue Virus (3) DNA Alkylator/Crosslinker (1) DNA/RNA Synthesis (1) Dopamine Receptor (1) Drug Derivative (3) Drug Intermediate (2) Drug Isomer (1) Drug Metabolite (10) Endogenous Metabolite (23) Environmental Pollutants (7) Epigenetic Reader Domain (2) Estrogen Receptor/ERR (2) Fatty Acid Synthase (FASN) (3) Ferroptosis (2) Flavivirus (3) Fluorescent Dye (1) FOXO (2) Fungal (10) FXR (7) G protein-coupled Bile Acid Receptor 1 (1) GLP Receptor (9) Glucocorticoid Receptor (2) Glucosylceramide Synthase (GCS) (2) GLUT (1) Glutathione Peroxidase (1) Glutathione S-transferase (3) Glycosidase (2) GSK-3 (2) Hedgehog (5) Histamine Receptor (1) HMG-CoA Reductase (HMGCR) (1) HSP (2) Insecticide (5) Insulin Receptor (11) Interleukin Related (4) Isotope-Labeled Compounds (10) JNK (5) Keap1-Nrf2 (5) Lactate Dehydrogenase (1) Lipase (3) Liposome (2) LYTACs (1) mAChR (2) MetAP (1) Methylenetetrahydrofolate Dehydrogenase (MTHFD) (1) METTL3 (1) Microtubule/Tubulin (3) Mixed Lineage Kinase (2) Monoamine Oxidase (2) mTOR (2) NADPH Oxidase (1) Necroptosis (2) NF-κB (7) NO Synthase (1) NOD-like Receptor (NLR) (2) Olfactory Receptor (1) Opioid Receptor (1) p38 MAPK (9) Parasite (7) PARP (4) PGC-1α (1) Phosphatase (2) PI3K (1) PKC (2) PPAR (13) Pregnane X Receptor (PXR) (4) PROTAC Linkers (2) PTHR (1) Pyroptosis (2) Pyruvate Kinase (1) Quinone Reductase (1) Reactive Oxygen Species (ROS) (5) Reference Standards (19) RIP kinase (2) Sirtuin (5) SOD (2) STAT (1) Stearoyl-CoA Desaturase (SCD) (1) Survivin (2) TGF-beta/Smad (2) TGF-β Receptor (2) TNF Receptor (7) Toll-like Receptor (TLR) (1) TRP Channel (3) UGT (1) α-synuclein (8) β-glucuronidase (1)
By Research Areas:	Cancer (52) Cardiovascular Disease (17) Endocrinology (8) Infection (30) Inflammation/Immunology (37) Metabolic Disease (87) Neurological Disease (23)
Oligonucleotides:	Cationic Lipids (1) Phospholipids (1) Cholesterol (2)

161

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Targets Recommended: LXR Mitochondrial Metabolism

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-114118

Semaglutide Maximum Cited Publications 35 Publications Verification	GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-N9933

Tauro-β-muricholic acid 4 Publications Verification TβMCA	FXR Apoptosis	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Tauro-β-muricholic acid (TβMCA) is an orally active trihydroxylated bile acid and a competitive, reversible FXR antagonist (IC₅₀=40 μM). Tauro-β-muricholic acid inhibits bile acid-induced hepatocyte apoptosis by maintaining mitochondrial membrane potential, while simultaneously inhibiting intestinal FXR signaling, affecting bile acid synthesis, hepatic lipid metabolism, and insulin sensitivity. Accumulation of tauro-β-muricholic acid disrupts metabolic homeostasis, promoting cancer stem cell proliferation and tumor progression. The mechanisms of tauro-β-muricholic acid involve two aspects: first, inhibiting the translocation of the pro-apoptotic protein Bax to mitochondria and maintaining mitochondrial membrane potential (MMP); and second, blocking the FXR signaling pathway to regulate bile acid metabolism, reduce serum ceramide production, and downregulate the hepatic SREBP1C/CIDEA pathway. Tauro-β-muricholic acid possesses anti-hepatocyte apoptosis, bile acid homeostasis regulation, and liver fat accumulation reduction properties, and also functions as a biomarker, making it useful in the study of diseases such as bile acid metabolism disorders, non-alcoholic fatty liver disease, colorectal cancer, and liver fibrosis .

HY-W040127

Peonidin 3-O-glucoside chloride 1 Publications Verification	Insulin Receptor	Metabolic Disease
Peonidin 3-O-glucoside chloride is an agonist of the free fatty acid receptor FFAR1 and Glucokinase. Peonidin 3-O-glucoside chloride enhances insulin secretion of pancreatic beta cells and increases glucose uptake by liver cells. Peonidin 3-O-glucoside chloride activates FFAR1, promotes the phosphorylation of related proteins in the insulin secretion pathway, and increases the expression of FFAR1. In liver cells, Peonidin 3-O-glucoside chloride activates GK and regulates proteins associated with carbohydrate metabolism. Peonidin 3-O-glucoside chloride can be used in diabetes research .

HY-114118B

Semaglutide acetate Maximum Cited Publications 35 Publications Verification	GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide acetate is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide acetate promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide acetate also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide acetate has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide acetate can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-114118A

Semaglutide TFA Maximum Cited Publications 35 Publications Verification	GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide TFA is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide TFA promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide TFA also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide TFA has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide TFA can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-N0010

Geniposidic acid Maximum Cited Publications 7 Publications Verification	FXR Sirtuin TNF Receptor Interleukin Related	Metabolic Disease
Geniposidic acid is an orally active FXR modulator and SIRT6 activator. Geniposidic acid binds to the Ser332 and His447 sites on the FXR ligand-binding domain, thereby driving nuclear translocation, coactivator recruitment, and transcription of downstream bile acid and cholesterol metabolism-related genes. Geniposidic acid improves metabolic dysfunction-related fatty liver disease by activating the SIRT6 signaling pathway. Geniposidic acid inhibits inflammation and modulates gut microbiota to alleviate colitis. Geniposidic acid can be used in research on drug-induced liver injury, inflammatory bowel disease, metabolic dysfunction-related fatty liver disease, and metabolic dysfunction-related steatohepatitis .

HY-112885A

nor-NOHA acetate 5 Publications Verification Nω-Hydroxy-nor-L-arginine acetate	Arginase Apoptosis	Cardiovascular Disease Infection Metabolic Disease Inflammation/Immunology Cancer
nor-NOHA acetate is a selective and reversible Arginase inhibitor. nor-NOHA acetate induces Apoptosis in ARG2-expressing cells under hypoxia. nor-NOHA acetate has anti-leukemic activity. nor-NOHA acetate improves liver ischemia-reperfusion injury. nor-NOHA acetate can used in study of tuberculosis, endothelial dysfunction, immunosuppression and metabolism .

HY-101036

Choline bitartrate 4 Publications Verification	mAChR Endogenous Metabolite	Neurological Disease Cancer
Choline bitartrate is a vitamin-like essential nutrient, can affect diseases such as liver disease, atherosclerosis and neurological disorders . Choline bitartrate is a precursor for the neurotransmitter acetylcholine, as a methyl donor in various metabolic processes, and in lipid metabolism .

HY-113081

1-Methyladenosine 4 Publications Verification	Endogenous Metabolite PPAR Hedgehog	Cancer
1-Methyladenosine is an RNA modification that can serve as a tumor marker, with elevated levels in the body associated with cancer development. Following 1-methyladenosine methylation, upregulation of PPARδ expression regulates cholesterol metabolism and activates Hedgehog signaling pathway, driving liver tumorigenesis .

HY-B0998

Dehydrocholic acid sodium Dehydrocholate sodium	Amylases Lipase Autophagy	Metabolic Disease
Dehydrocholic acid (Dehydrocholate) sodium is an orally active hydrocholeretic agent. Dehydrocholic acid sodium modulates Autophagy, reduces serum amylase and lipase levels. Dehydrocholic acid sodium has the effects of promoting choleretic function, protecting the liver, reducing pancreatic damage, and regulating cholesterol metabolism. Dehydrocholic acid sodium can be used in the study of acute biliary pancreatitis and obstructive jaundice .

HY-112885C

nor-NOHA dihydrochloride 5 Publications Verification Nω-Hydroxy-nor-L-arginine dihydrochloride	Apoptosis Arginase	Cardiovascular Disease Infection Metabolic Disease Inflammation/Immunology Cancer
nor-NOHA dihydrochloride is a selective and reversible Arginase inhibitor. nor-NOHA dihydrochloride induces Apoptosis in ARG2-expressing cells under hypoxia. nor-NOHA dihydrochloride has anti-leukemic activity. nor-NOHA dihydrochloride improves liver ischemia-reperfusion injury. nor-NOHA dihydrochloride can used in study of tuberculosis, endothelial dysfunction, immunosuppression and metabolism .

HY-114118CP

Semaglutide (crude)	GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide (crude) is the crude form of Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances Autophagy, inhibits oxidative stress and Apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-114118S3

Semaglutide-13C6,15N TFA	Isotope-Labeled Compounds GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Metabolic Disease
Semaglutide- ¹³C₆, ¹⁵N TFA is the ¹³C- and ¹⁵N-labeled Semaglutide TFA (HY-114118A). Semaglutide TFA is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide TFA promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide TFA also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide TFA has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide TFA can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-15259

CP-640186 5+ Cited Publications	Acetyl-CoA Carboxylase	Metabolic Disease
CP-640186 is an orally active and cell-permeable Acetyl-CoA carboxylase (ACC) inhibitor with IC₅₀s of 53 nM and 61 nM for rat liver ACC1 and rat skeletal muscle ACC2 respectively. Acetyl-CoA carboxylase (ACC) is a key enzyme of fatty acid metabolism that enables the synthesis of malonyl-CoA. CP-640186 can also stimulate muscle fatty acid oxidation .

HY-W587530

6-Oxolithocholic acid 6-Ketolithocholic acid	Endogenous Metabolite Apoptosis	Endocrinology
6-Oxolithocholic acid is a bile acid metabolite derived from Lithocholic acid (HY-B0172). 6-Oxolithocholic acid has high cytotoxicity and can induce apoptosis, especially in hepatocytes. 6-Oxolithocholic acid can participate in the regulation of bile acid metabolism and synthesis and affect the metabolic pathway of cholesterol. 6-Oxolithocholic acid can be used to study the role of bile acids in health and disease, especially in the context of digestive and liver diseases .

HY-W020012

Fluoresterol 22-NBD Cholesterol	Fluorescent Dye	Metabolic Disease
Fluoresterol (22-NBD Cholesterol) is a cholesterol-specific fluorescent probe with cholesterol-mimicking binding properties. Fluoresterol is ineffective orally and does not cross the blood-brain barrier. Fluoresterol specifically binds to cholesterol transport-related proteins (such as ABCA1 and ABCG1) and is primarily used in cholesterol metabolism research, particularly for the visualization and quantitative analysis of cholesterol absorption, efflux, intracellular transport efficiency, and reverse cholesterol transport (RCT) processes. The commonly used concentration of Fluoresterol in in vitro experiments is 0.1-10 μM, and the commonly used dose in in vivo experiments is 5-20 mg/kg (gavage or intraperitoneal injection), with excitation/emission wavelengths of 472/540 nm. Fluoresterol can be applied to the study of cholesterol metabolism mechanisms related to hyperlipidemia, atherosclerosis, and non-alcoholic fatty liver disease (NAFLD) .

HY-P2994

3-Hydroxybutyrate dehydrogenase 3-HBDH	Endogenous Metabolite	Metabolic Disease
3-Hydroxybutyrate dehydrogenase (3-HBDH), a mitochondrial enzyme, is a key enzyme in the ketone body metabolism pathway. 3-Hydroxybutyrate dehydrogenase is the last enzyme for ketone synthesis in the liver and the first enzyme for ketone breakdown in extracellular tissues. The absence of 3-Hydroxybutyrate dehydrogenase leads to the inhibition of fatty acid oxidation in the liver during fasting in mice, resulting in lipid accumulation and the development of fatty liver .

HY-W015608

2-Phenylpropionic acid	Endogenous Metabolite	Metabolic Disease
2-Phenylpropionic acid is an intermediate in the metabolism of alpha-Methylstyrene. 2-Phenylpropionic acid covalently binds to rat liver protein. 2-Phenylpropionic acid can be used in the research of nonsteroidal anti-inflammatory agents .

HY-N0546

Ligustroflavone 2 Publications Verification Nuezhenoside	CaSR RIP kinase Mixed Lineage Kinase TGF-beta/Smad	Cardiovascular Disease Neurological Disease Metabolic Disease Endocrinology
Ligustroflavone is an orally active flavonoid compound. Ligustroflavone can be extracted from Ligustrum lucidum. Ligustroflavone antagonizes the calcium-sensing receptor (CaSR), inhibits the RIPK1/RIPK3/MLKL pathway, and downregulates TGF-β/Smad signaling. Ligustroflavone regulates calcium metabolism, protects bone tissue, reduces cerebral ischemic injury, and inhibits liver fibrosis. Ligustroflavone can be used in the study of diabetic osteoporosis, ischemic stroke, and liver fibrosis .

HY-N2181

Acetylshikonin 3 Publications Verification	Cytochrome P450 Apoptosis Bacterial Autophagy	Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Acetylshikonin is an oral active anti-cancer, anti-inflammatory, antioxidant, anti-fertility, antibacterial, and neuroprotective agent. Acetylshikonin is a inhibitor of acetylcholinase (AChE) (IC₅₀=34.6 μM) and nonselective cytochrome P450. Acetylshikonin can induce Apoptosis and Autophagy in cancer cells. Acetylshikonin regulates blood glucose, liver fat metabolism, and renal fibrosis, and is used in the study of diabetes, diabetic nephropathy (DN), obesity, and nonalcoholic fatty liver disease (NAFLD) .

HY-W018004

L-Homocitrulline	Amino Acid Derivatives Endogenous Metabolite	Inflammation/Immunology
L-Homocitrulline is a carbamoylated derivative amino acid and a structural analog of L-citrulline. L-Homocitrulline serves not only as an intermediate in polypeptide synthesis but also converts into a variety of cyclic derivatives under enzymatic or acidic conditions. The level of L-Homocitrulline is significantly elevated in the serum of patients with non-alcoholic fatty liver disease (NAFLD), with high diagnostic accuracy. L-Homocitrulline also exists in patients with related diseases such as hypercitrullinemia. L-Homocitrulline is a key biomarker for monitoring abnormal liver metabolism and is widely used in NAFLD research .

HY-W355700

1-Oleoyl-2-hydroxy-sn-glycero-3-phosphoethanolamine	Drug Metabolite	Infection
1-oleoyl-sn-glycero-3-phosphoethanolamine (LysoPE 18:1) is a lysophosphatidylethanolamine molecule involved in phospholipid metabolism, targeting cell membrane receptors (such as G protein-coupled receptors) to regulate cell signaling pathways. 1-oleoyl-sn-glycero-3-phosphoethanolamine may activate mitogen-activated protein kinase (MAPK) signaling, promote cell migration, regulate inflammatory responses and lipid metabolism, and has both pro-inflammatory and anti-inflammatory activities. 1-oleoyl-sn-glycero-3-phosphoethanolamine is mainly used in the screening of biomarkers for metabolic diseases (such as non-alcoholic fatty liver disease and obesity), as well as the study of the mechanism of lysophospholipids in cell membrane homeostasis and signal transduction .

HY-133971

Cholesterol 5α,6α-epoxide 5α,6α-Epoxycholesterol	Liposome	Others
Cholesterol-5α,6α-epoxide is an epoxide derivative of cholesterol formed by the enzymatic oxidation of cholesterol in the liver and other tissues. Cholesterol-5α,6α-epoxide has unique chemical properties that make it an important intermediate in the biosynthesis of bile acids, which play a key role in the digestion and absorption of dietary fats. It also has a potential physiological role in regulating cholesterol metabolism and transport, although its biological function is not fully understood.

HY-B1311

Proadifen hydrochloride 1 Publications Verification SKF-525A; U-5446; RP-5171	Cytochrome P450 Monoamine Oxidase Bcl-2 Family Survivin PARP	Neurological Disease Inflammation/Immunology Cancer
Proadifen (SKF-525A) hydrochloride is a non-competitive Cytochrome P450 inhibitor with an IC₅₀ value of 19 μM. Proadifen hydrochloride reduces monoamine oxidase A (MAO-A) activity and reverses the antidepressantlike behavioral effect of Imipramine (HY-B1490A) and Desipramine (HY-B1272A) in rats. Proadifen hydrochloride also reduces N, N-dimethyltryptamine (DMT) metabolism in liver microsomes and inhibits N-demethylationand Acridone (HY-W007771) formation. Proadifen hydrochloride augments Lipopolysaccharide (LPS) (HY-D1056)-induced fever and exacerbates Prostaglandin E2 (PGE2) (HY-101952) levels in the rat. Proadifen hydrochloride is promising for research of metabolism-related deseases, ovarian carcinoma, inflammation and dopamine neurons-related deseases .

HY-108022A

Azemiglitazone potassium 1 Publications Verification MSDC-0602K	Insulin Receptor PPAR	Metabolic Disease
Azemiglitazone potassium (MSDC-0602K), a PPARγ-sparing thiazolidinedione (Ps-TZD), binds to PPARγ with the IC₅₀ of 18.25 μM . Azemiglitazone potassium modulates the mitochondrial pyruvate carrier (MPC). Azemiglitazone potassium can be used for the research of fatty liver including dysfunctional lipid metabolism, inflammation, and insulin resistance . Azemiglitazone potassium, an insulin sensitizer, improves insulinemia and fatty liver disease in mice, alone and in combination with Liraglutide .

HY-E70558

5α-reductase, Rat(Sprague-Dawley) Liver	5 alpha Reductase	Metabolic Disease
5α-reductase, Rat (Sprague-Dawley) Liver is an enzyme involved in steroid metabolism and participates in the androgen metabolic pathway. 5α-reductase, Rat (Sprague-Dawley) Liver catalyzes the conversion of testosterone to 5α-dihydrotestosterone (DHT). DHT plays important roles in the development of male sex organs, hair growth, prostate function, and other aspects .

HY-B1134

Imazalil 1 Publications Verification Enilconazole	Environmental Pollutants Fungal Pregnane X Receptor (PXR)	Infection
Imazalil (Enilconazole) is a fungicide. Imazalil has oral activity and strongly activates mPXR but not mCAR in mouse liver. Imazalil is commonly used to protect various agricultural crops against fungal attack. Imazalil induces developmental abnormalities, gut microbiota dysbiosis, and hepatic metabolism disorder .

HY-N0385

Gomisin J 3 Publications Verification	NO Synthase AMPK CaMK NF-κB Keap1-Nrf2	Cardiovascular Disease Inflammation/Immunology
Gomisin J is a Schisandra chinensis-derived lignan that can inhibit multiple targets such as eNOS, AMPK (LKB1, CaMKIIβ), fetuin-A, NF-κB, Nrf2/HO-1, and can pass through the blood-brain barrier. Gomisin J increases NO bioavailability by activating eNOS, regulates lipid metabolism by activating the AMPK pathway, inhibits fetuin-A and NF-κB to exert anti-inflammatory effects, and activates Nrf2/HO-1 to enhance antioxidant capacity. Gomisin J has the activities of anti-hypertension, regulating liver lipid metabolism, and reducing cerebral ischemia-reperfusion injury, and can be used for research on hypertension, non-alcoholic fatty liver disease, cerebral ischemia-reperfusion injury, etc .

HY-B1393

Dehydrocholic acid Dehydrocholate	Autophagy Amylases Lipase	Metabolic Disease
Dehydrocholic acid (Dehydrocholate) is an orally active hydrocholeretic agent. Dehydrocholic acid modulates Autophagy, reduces serum amylase and lipase levels. Dehydrocholic acid has the effects of promoting choleretic function, protecting the liver, reducing pancreatic damage, and regulating cholesterol metabolism. Dehydrocholic acid can be used in the study of acute biliary pancreatitis and obstructive jaundice .

HY-15259A

CP-640186 hydrochloride 5+ Cited Publications	Acetyl-CoA Carboxylase	Metabolic Disease
CP-640186 hydrochloride is an orally active and cell-permeable Acetyl-CoA carboxylase (ACC) inhibitor with IC₅₀s of 53 nM and 61 nM for rat liver ACC1 and rat skeletal muscle ACC2 respectively. Acetyl-CoA carboxylase (ACC) is a key enzyme of fatty acid metabolism that enables the synthesis of malonyl-CoA. CP-640186 hydrochloride can also stimulate muscle fatty acid oxidation .

HY-114118S1

Semaglutide-d8 tetraTFA	Isotope-Labeled Compounds GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide-d₈ tetraTFA is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-114118S

Semaglutide-d8	Isotope-Labeled Compounds GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide-d₈ is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-N10549

Gigantol 1 Publications Verification	Ferroptosis c-Myc Glutathione Peroxidase JNK Reactive Oxygen Species (ROS) GSK-3	Infection Metabolic Disease Cancer
Gigantol is an orally active bibenzyl compound. Gigantol targets MYC to promote its ubiquitin-proteasomal degradation and inhibit the growth of lung cancer cells. Gigantol exerts anti-lung cancer activity by inducing ferroptosis (Ferroptosis) via the SLC7A11-GPX4 axis. Gigantol restores the sensitivity of mcr-harboring multidrug-resistant bacteria to colistin. Gigantol ameliorates carbon tetrachloride-induced liver injury by inhibiting the activation of the JNK/cPLA2/12-LOX inflammatory pathway. Gigantol promotes cholesterol metabolism and progesterone biosynthesis in Leydig cells. Gigantol can be used in studies related to diseases such as lung cancer, multidrug-resistant Gram-negative bacterial infections, and acute liver injury .

HY-177704

ACSL5-IN-1	ACSL Family Drug Derivative	Metabolic Disease Cancer
ACSL5-IN-1 (Compound A) is an ACSL5 inhibitor with body weight-reducing activity. ACSL5-IN-1 inhibits ACSL5, an enzyme linked to fatty acid metabolism. ACSL5-IN-1 reduces body weight in diet-induced obesity mice. ACSL5-IN-1 can be used for the research of obesity, metabolic dysfunction-associated steatohepatitis, metabolic syndrome, non-alcoholic fatty liver disease, type 2 diabetes, acute myeloid leukemia, colorectal cancer, and breast cancer .

HY-124098

Lignocaine N-oxide Lidocaine N-oxide	Drug Metabolite	Others
Lignocaine N-oxide (Lidocaine N-oxide) is a compound derived from the metabolism of lidocaine. Lidocaine can be metabolized to its N-oxide in rat liver microsomes.

HY-122373

Coprine	Aldehyde Dehydrogenase (ALDH) Drug Derivative	Metabolic Disease
Coprine is an orally active disulfiram (HY-B0240)-like component and an inhibitor of aldehyde dehydrogenase. Coprine is isolated from Coprinus atranentarius. Coprine inhibits low K_m aldehyde dehydrogenase in rat liver and increases blood acetaldehyde levels during in vivo ethanol metabolism. Coprine does not inhibit semi-purified low K_m aldehyde dehydrogenase from rat liver in vitro. Coprine can be used in studies related to alcoholism .

HY-B1858

Isoprothiolane 2 Publications Verification	Environmental Pollutants Parasite Fungal Interleukin Related	Infection Metabolic Disease Inflammation/Immunology
Isoprothiolane is a blast fungicide with antifungal, anti-inflammatory and insecticidal activities. Isoprothiolane primarily acts on fungi during the penetration and growth stages of infecting hyphae. Isoprothiolane can be used as an insecticide, pesticide, etc. In addition, Isoprothiolane can reduce serum phospholipid and total lipid concentrations, regulating lipid metabolism. Isoprothiolane is also used in the research of fatty liver .

HY-B0854

Mancozeb	Environmental Pollutants Lactate Dehydrogenase Apoptosis Fungal Cytochrome P450 Keap1-Nrf2	Infection Metabolic Disease Cancer
Mancozeb is a widely used fungicide that is effective against fungal diseases in most cereals, vegetables, fruits and ornamental plants. In addition, Mancozeb can cause liver damage in mice by activating the Keap1/Nrf2 signaling pathway. Mancozeb upregulates lactate dehydrogenase and cytochrome c to alter cell metabolism and induce cell death. Mancozeb has reproductive toxicity and can induce apoptosis in ovarian cells .

HY-117006

E1231 1 Publications Verification 1-{4-[2-(5-Methylfuran-2-yl)quinoline-4-carbonyl]piperazin-1-yl}ethan-1-one	Sirtuin	Cardiovascular Disease
E1231 is an orally active activator of Sirtuin 1 (SIRT1) (EC₅₀=0.83 μM), to modulate cholesterol and lipid metabolism. E1231 interactes with SIRT1 (K_D=9.61 μM) and deacetylated liver X receptor-alpha (LXRα), and increases ATP-binding cassette transporter A1 (ABCA1) expression. E1231 also reduces atherosclerotic plaque development in ApoE ^-/- mice model. E1231 can be used for research in cholesterol and lipid disorder-related diseases .

HY-129491

O-Desmethyl Midostaurin CGP62221; O-Desmethyl PKC412	PKC	Cancer
O-Desmethyl Midostaurin (CGP62221; O-Desmethyl PKC412) is the active metabolite of Midostaurin (HY-10230) via cytochrome P450 liver enzyme metabolism. O-Desmethyl Midostaurin can be used as an indicator for Midostaurin metabolism in vivo . Midostaurin is a multi-targeted protein kinase inhibitor with IC₅₀ ranging from 22-500 nM.

HY-113081R

1-Methyladenosine (Standard)	Reference Standards Endogenous Metabolite PPAR Hedgehog	Cancer
1-Methyladenosine (Standard) is the analytical standard of 1-Methyladenosine. This product is intended for research and analytical applications. 1-Methyladenosine is an RNA modification that can serve as a tumor marker, with elevated levels in the body associated with cancer development. Following 1-methyladenosine methylation, upregulation of PPARδ expression regulates cholesterol metabolism and activates Hedgehog signaling pathway, driving liver tumorigenesis . In Vitro:Compared to surrounding tumor tissues, 1-methyladenosine methylation in RNA is aberrantly elevated in hepatocellular carcinoma (HCC) cell lines and liver cancer stem cells (CSCs). Methylated 1-methyladenosine can promote cholesterol synthesis and activate the Hedgehog signaling pathway by enhancing the translation of PPARδ in liver CSCs, ultimately driving the self-renewal and tumorigenesis of liver cancer stem cells .

HY-145368B

Tri-GalNAc(OAc)3-Perfluorophenyl	LYTACs	Metabolic Disease
Tri-GalNAc(OAc)3-Perfluorophenyl is a pentafluorophenyl modified Tri-GalNAc(OAc)3 (HY-148118), a tri-GalNAc ligand that can be used for the synthesis of GalNAc-LYTAC. GalNAc-LYTAC engages the asialoglycoprotein receptor for targeted protein degradation.Tri-GalNAc(OAc)3-Perfluorophenyl can be used for the study of liver metabolism .

HY-116568

Prothioconazole JAU-6476	Fungal Cytochrome P450 Microtubule/Tubulin Mitochondrial Metabolism DNA/RNA Synthesis Apoptosis Fatty Acid Synthase (FASN)	Infection Metabolic Disease Endocrinology
Prothioconazole is an orally active broad-spectrum fungicide. Prothioconazole weakly inhibits CaCYP51 activity in Candida albicans, with an apparent IC₅₀ of approximately 120 μM. Prothioconazole disrupts Microtubule stability by reducing the acetylation level of α-tubulin. Prothioconazole induces Mitochondrial dysfunction, oxidative stress, DNA damage, and Apoptosis. Prothioconazole accumulates ¹⁴-methylated sterols and depletes ergosterol in cells, culture media, plants, and animals. Prothioconazole interferes with pyruvate metabolism and glycolysis/gluconeogenesis processes in mouse liver, downregulates Fasn mRNA expression, and induces hepatotoxicity and renal metabolic disorders. Prothioconazole reduces the fertility of female mice. Prothioconazole inhibits body weight gain and increases liver/kidney indices in mice. Prothioconazole can be used in studies related to candidiasis .

HY-N4031

Humantenine	Anaplastic lymphoma kinase (ALK) METTL3	Inflammation/Immunology
Humantenine is a highly toxic indole alkaloid from Gelsemium elegans (Gardn. & Champ.) Benth. that binds to RNA m6A modification regulatory proteins (ALKBH5, METTL). Humantenine stably binds via hydrogen bonding and hydrophobic interactions and disrupts the m6A methylation level of target genes, thereby impairing the expression of intestinal epithelial cell tight junction and cytoskeleton-related genes, causing intestinal barrier dysfunction and significant intestinal cytotoxicity. The intraperitoneal injection LD₅₀ values of Humantenine are <1 mg/kg in mice, 1.2 mg/kg in male rats and 1.5 mg/kg in female rats, respectively. Species differences exist in the metabolism of Humantenine in human, porcine, goat and rat liver microsomes, and demethylation, dehydrogenation and oxidation occur in liver microsomes .

HY-168049

ZLY06	PPAR Akt	Metabolic Disease
ZLY06 is an orally active dual agonist of peroxisome proliferator-activated receptor (PPAR) δ and γ (PPAR δ: EC₅₀=341 nM; PPAR γ: EC₅₀=237 nM). ZLY06 induces hepatic lipid accumulation by inhibiting the phosphorylation of AKT1, mediating the upregulation of CD36. In addition, ZLY06 significantly improves glucose and lipid metabolism without increasing body weight, and alleviates fatty liver by promoting β-oxidation of fatty acids and inhibiting hepatic lipogenesis .

HY-W414823

24,25-Epoxycholesterol	LXR HMG-CoA Reductase (HMGCR)	Metabolic Disease
24,25-Epoxycholesterol is an oxysterol agonist of the liver X receptor that can inhibit the activity of 3-hydroxy-3-methylglutaryl-CoA reductase (HMG-CoA reductase) in liver cells. 24,25-Epoxycholesterol regulates cholesterol metabolism in the liver .

HY-W591838

Perfluoropentanesulfonic acid PFPeS	Biochemical Assay Reagents Phosphatase	Metabolic Disease
Perfluoropentanesulfonic acid (PFPeS) is a per- and polyfluoroalkyl substance. Perfluoropentanesulfonic acid increases alkaline phosphatase (ALKP). Perfluoropentanesulfonic acid induces systemic toxicity in mouse models and alters the expression of genes related to fatty acid metabolism, inflammation and skin integrity in the liver and skin .

HY-119669

Furylfuramide	Bacterial	Others
Furylfuramide is a food preservative that exhibits mutagenic activity. Furylfuramide can be degraded through the aerobic metabolism by liver microsomes .

HY-B1351

Bilberry Extract	Cytochrome P450	Metabolic Disease
Bilberry Extract is a bilberry extract, and its components include: Anthocyanidins. Bilberry Extract has potential antioxidant activity and can regulate specific metabolic enzymes in the liver, such as cytochrome P450 (CYP) 2C11 and CYP2E1 involved in drug metabolism. .

HY-109690

1-(2-Amino-3-hydroxyphenyl)ethanone	Endogenous Metabolite	Cancer
1-(2-Amino-3-hydroxyphenyl)ethanone is the kynuridine metabolite, which could be extracted from rat liver mitochondrium. 1-(2-Amino-3-hydroxyphenyl)ethanone is associated with tryptophan metabolism disturbances, and can be used in bladder cancer, leukemia and anemia researches .

Cat. No.	Product Name

HY-L208

Bile Acids Library

61 compounds

Bile acids are a class of amphiphilic molecules derived from the metabolic breakdown of cholesterol, primarily synthesized in the liver, and play a crucial role in the intestines. Based on their structural characteristics, bile acids are mainly divided into two categories: free bile acids (including Cholic acid, Deoxycholic acid, Chenodeoxycholic acid) and conjugated bile acids (including Glycocholic acid, Glycochenodeoxycholic acid, Taurocholic acid, etc.). Bile acids play a significant role in the pathophysiological research of liver and gastrointestinal diseases and are closely associated with the occurrence of metabolic diseases such as obesity, type II diabetes, non-alcoholic fatty liver disease, and atherosclerosis. Bile acids maintain metabolic balance within the body by regulating sugar metabolism, lipid metabolism, and amino acid metabolism, and they influence the activity of metabolism-related enzymes and transporters. In addition, Bile acids can also be used to construct a bile acid metabolism research platform, which helps to delve into the metabolic pathways and dynamic changes of bile acids in living organisms and aids in identifying new biomarkers for certain diseases.

MCE included 61 bile acids, including Cholic acid, Deoxycholic acid, Glycocholic acid, etc., which are effective tools for the study of liver and gallbladder diseases.

HY-L091

Lipid Metabolism Compound Library

978 compounds

Lipids are a fundamental class of organic molecules implicated in a wide range of biological processes, and based on this can be broadly classified into five categories: fatty acids, triacylglycerols (TAGs), phospholipids, sterol lipids and sphingolipids. Lipids play a crucial role in different metabolic pathways and cellular functions. Lipid metabolism is an important physiological process that is related to nutrient adjustment, hormone regulation, and homeostasis. Lipid metabolism dysregulation is associated with many diseases such as obesity, liver disease, aging and inflammation.

MCE offers a unique collection of 978 compounds related to lipid metabolism, which target relevant targets in the process of lipid metabolism, such as ATGL, MAGL, FAAH, acetyl-Coa Carboxylase, FASN, etc. MCE lipid metabolism compound library is a useful tool for research lipid metabolism and drug discovery of diseases related to lipid metabolism.

HY-L182

Fatty Acids Compound Library

285 compounds

Fatty acids (FAs) are the main components of lipids. The synthesis of fatty acids mainly involves the Triglyceride (TG) cycle and De Novo Lipogenesis (DNL). Fatty acids which exist widely in organisms are components of cell membranes and play an indispensable role in cell signaling. In addition, FFAs can be taken up from circulating plasma by all mitochondria-containing cells, and they are metabolized by β-oxidation and the citric acid cycle to release large amounts of energy in the form of ATP. Abnormal fatty acid metabolism is associated with the occurrence and development of cardiovascular diseases, diabetes, fatty liver, hyperthyroidism, and other diseases.

MCE offers a unique collection of fatty acid compounds. Fatty Acids Compound Library is an important tool for the study of energy metabolism and drug development of metabolism-related diseases.

HY-L228

Lipid Metabolite Compound Library

145 compounds

Lipids are important energy storage substances in the human body. They are involved in the regulation of cell structure and function, as well as signaling pathways and gene expression. Abnormal lipid levels in tissues or their dysregulation can lead to various diseases. These include obesity, type 2 diabetes, non-alcoholic fatty liver disease, neurodegenerative diseases, infections, and cancer. Therefore, maintaining normal levels of lipid metabolism is critical to overall health.

One of the key features of cancer is aberrant lipid metabolism. This includes alterations in lipid uptake, lipid desaturation, neolipogenesis, lipid droplets, and fatty acid oxidation in cancer cells. These changes all contribute to cellular survival in an ever-changing microenvironment. They do this by modulating feed-forward oncogenic signals and key oncogenic functions. Additionally, they affect oxidative stress, other types of stress, immune responses, and intercellular communication. Alterations in lipid metabolism have a strong impact on the properties of cancer stem cells. This includes aspects such as self-renewal, differentiation, invasion, metastasis, drug sensitivity, and resistance. Furthermore, these alterations also modulate T cell responses.

MCE can offer 145 metabolites of lipid metabolism pathways, which can be used for drug screening in cancer, immune-based diseases, metabolic diseases, and other diseases.

HY-L155

Mitochondrial Toxicity Compound Library

535 compounds

Mitochondria, as the main place of energy supply in life, is essential to maintain normal life activities. Mitochondrial dysfunction is associated with common diseases, such as cardiovascular diseases, neurodegenerative diseases, diabetes and cancer. The heart, brain and liver rely heavily on mitochondrial function as the main organs for drug metabolism. In addition, mitochondria is also a target of many drugs, some of which induce organotoxicity by inducing mitochondrial toxicity.

MCE contains 535 mitochondrial toxic compounds, which can be used as tool compounds for drug development and disease mechanism research.

HY-L087

Anti-Obesity Compound Library

3,558 compounds

Obesity is widely recognized as the largest and fastest growing public health problem and is associated with numerous chronic disorders including osteoarthritis, obstructive sleep apnea, gallstones, fatty liver disease, reproductive and gastrointestinal cancers, dyslipidemia, hypertension, type 2 diabetes, heart failure, coronary artery disease, stroke, etc. Although obesity has long been associated with serious health issues, it has only recently been regarded as a disease in the sense of being a specific target for medical therapy. Obesity may be viewed as the dysregulation of two physiological functions, appetite regulation and energy metabolism, which combine to create disordered energy balance. Consequently, developing obesity treatments that target novel pathways is a growing focus for both biopharmaceutical industries.

MCE Anti-Obesity Compound Library owns a unique collection of 3,558 compounds, which mainly target signaling pathway of controlling appetite, fatty acid metabolism and energy expenditure, etc. This library is a useful tool for discovery anti-obesity drugs.

Cat. No.	Product Name	Type

HY-134816

D-Glucan

Biochemical Assay Reagents

D-Glucan is an orally effective Dectin-1 receptor immune activator with antioxidant properties (reducing TNF-α). D-Glucan activates macrophages and neutrophils to scavenge free radicals, inhibit oxidative stress and inflammatory responses, and improve insulin sensitivity. D-Glucan promotes glycolysis by enhancing the activity of the antioxidant enzyme glutathione, inhibiting gluconeogenesis and activating GK. D-Glucan can be used in the research of liver damage protection (antagonizing Acetaminophen (HY-66005) toxicity), radiation protection (synergistic with vitamin E) and diabetes (improving glucose metabolism) .

HY-133971

Cholesterol 5α,6α-epoxide

5α,6α-Epoxycholesterol

Biochemical Assay Reagents

Cholesterol-5α,6α-epoxide is an epoxide derivative of cholesterol formed by the enzymatic oxidation of cholesterol in the liver and other tissues. Cholesterol-5α,6α-epoxide has unique chemical properties that make it an important intermediate in the biosynthesis of bile acids, which play a key role in the digestion and absorption of dietary fats. It also has a potential physiological role in regulating cholesterol metabolism and transport, although its biological function is not fully understood.

Cat. No.	Product Name	Target	Research Area

HY-114118

Semaglutide Maximum Cited Publications 35 Publications Verification	GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-114118B

Semaglutide acetate Maximum Cited Publications 35 Publications Verification	GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide acetate is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide acetate promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide acetate also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide acetate has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide acetate can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-114118A

Semaglutide TFA Maximum Cited Publications 35 Publications Verification	GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide TFA is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide TFA promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide TFA also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide TFA has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide TFA can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-108743

Insulin degludec	Insulin Receptor	Endocrinology
Insulin degludec is an ultra-long-acting form of insulin used for the research of hyperglycemia caused by type 1 and type 2 dabetes. Insulin degludec shows binding efficiency with an IC₅₀ value of 19.59 nM for insulin receptor. Insulin degludec can be used for the research of type 1 and type 2 diabetes .

HY-114118CP

Semaglutide (crude)	GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide (crude) is the crude form of Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances Autophagy, inhibits oxidative stress and Apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-114118S1

Semaglutide-d8 tetraTFA	Isotope-Labeled Compounds GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide-d₈ tetraTFA is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-114118S

Semaglutide-d8	Isotope-Labeled Compounds GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide-d₈ is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-P11358

IRW	Angiotensin-converting Enzyme (ACE) Acetyl-CoA Carboxylase Mitochondrial Metabolism	Inflammation/Immunology
IRW is an orally active tripeptide produced from egg white with angiotensin converting enzyme (ACE) inhibitory properties. IRW can prevent high-fat diet (HFD)-induced Non-alcoholic fatty liver disease (NAFLD) by modulating hepatic lipid metabolism and increasing mitochondrial content. IRW decreases hepatic triglyceride content and lipid droplet size. IRW increases the hepatic mitochondrial complexes and citrate synthase activity, phosphorylation of 5’-AMP-activated protein kinase and microsomal triglyceride transfer protein abundance. IRW increases phosphorylated acetyl CoA carboxylase and mitochondrial complexes, IRW can be used for the research of inflammation .

HY-114118C

Semaglutide sodium	GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide sodium is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide sodium promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide sodium also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide sodium has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide sodium can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N7075

Inulin 4 Publications Verification	Structural Classification Human Gut Microbiota Metabolites Polysaccharides Classification of Application Fields Metabolic Disease Plants Compositae Endogenous metabolite Disease Research Fields Saccharides Sophora tomentosa L. Source Classification	Endogenous Metabolite
Inulin is an orally active prebiotic targeting the intestinal microbiota, selectively promoting the proliferation and activity of beneficial bacteria such as bifidobacteria and lactic acid bacteria, and playing a role in regulating the intestinal microecology. The functions of Inulin include: Fermentation by probiotics in the colon to produce short-chain fatty acids (such as butyrate and propionate), lowering the intestinal pH and inhibiting the overgrowth of harmful bacteria; Enhancing the intestinal barrier function and reducing endotoxin translocation; Directly scavenging free radicals (such as superoxide free radicals, hydroxyl free radicals) and activating antioxidant enzymes (SOD, CAT) to reduce oxidative stress. Inulin can also be used in the study of intestinal diseases (constipation, IBD), metabolic syndrome (diabetes, obesity) and liver damage by regulating glucose and lipid metabolism (such as reducing triglycerides, improving insulin sensitivity) and immune response (enhancing NK cell activity, inhibiting inflammatory factors)[1][2][3][4].

HY-N9933

Tauro-β-muricholic acid 4 Publications Verification TβMCA	Structural Classification Human Gut Microbiota Metabolites Animals Endogenous metabolite Steroids Source Classification	FXR Apoptosis
Tauro-β-muricholic acid (TβMCA) is an orally active trihydroxylated bile acid and a competitive, reversible FXR antagonist (IC₅₀=40 μM). Tauro-β-muricholic acid inhibits bile acid-induced hepatocyte apoptosis by maintaining mitochondrial membrane potential, while simultaneously inhibiting intestinal FXR signaling, affecting bile acid synthesis, hepatic lipid metabolism, and insulin sensitivity. Accumulation of tauro-β-muricholic acid disrupts metabolic homeostasis, promoting cancer stem cell proliferation and tumor progression. The mechanisms of tauro-β-muricholic acid involve two aspects: first, inhibiting the translocation of the pro-apoptotic protein Bax to mitochondria and maintaining mitochondrial membrane potential (MMP); and second, blocking the FXR signaling pathway to regulate bile acid metabolism, reduce serum ceramide production, and downregulate the hepatic SREBP1C/CIDEA pathway. Tauro-β-muricholic acid possesses anti-hepatocyte apoptosis, bile acid homeostasis regulation, and liver fat accumulation reduction properties, and also functions as a biomarker, making it useful in the study of diseases such as bile acid metabolism disorders, non-alcoholic fatty liver disease, colorectal cancer, and liver fibrosis .

HY-W040127

Peonidin 3-O-glucoside chloride 1 Publications Verification	Anthocyans Flavonoids Classification of Application Fields Vitis vinifera cv. Zalema Metabolic Disease Plants Vitaceae Disease Research Fields Source Classification	Insulin Receptor
Peonidin 3-O-glucoside chloride is an agonist of the free fatty acid receptor FFAR1 and Glucokinase. Peonidin 3-O-glucoside chloride enhances insulin secretion of pancreatic beta cells and increases glucose uptake by liver cells. Peonidin 3-O-glucoside chloride activates FFAR1, promotes the phosphorylation of related proteins in the insulin secretion pathway, and increases the expression of FFAR1. In liver cells, Peonidin 3-O-glucoside chloride activates GK and regulates proteins associated with carbohydrate metabolism. Peonidin 3-O-glucoside chloride can be used in diabetes research .

HY-N0010

Geniposidic acid Maximum Cited Publications 7 Publications Verification	Structural Classification other families Iridoids Classification of Application Fields Terpenoids Plants Endogenous metabolite Disease Research Fields Source Classification Cancer	FXR Sirtuin TNF Receptor Interleukin Related
Geniposidic acid is an orally active FXR modulator and SIRT6 activator. Geniposidic acid binds to the Ser332 and His447 sites on the FXR ligand-binding domain, thereby driving nuclear translocation, coactivator recruitment, and transcription of downstream bile acid and cholesterol metabolism-related genes. Geniposidic acid improves metabolic dysfunction-related fatty liver disease by activating the SIRT6 signaling pathway. Geniposidic acid inhibits inflammation and modulates gut microbiota to alleviate colitis. Geniposidic acid can be used in research on drug-induced liver injury, inflammatory bowel disease, metabolic dysfunction-related fatty liver disease, and metabolic dysfunction-related steatohepatitis .

HY-125848

Ginsenoside F2	Panax ginseng C. A. Meyer Triterpenes Structural Classification Classification of Application Fields Terpenoids Plants Endogenous metabolite Disease Research Fields Araliaceae Source Classification Cancer	Apoptosis AMPK PPAR p38 MAPK PI3K Akt GSK-3 Reactive Oxygen Species (ROS) SOD Caspase
Ginsenoside F2 is an orally active bioactive compound that participates in the regulation of metabolism and inflammation. Ginsenoside F2 promotes the phosphorylation of AMPK and ACC, binds to PPARγ, inhibits the phosphorylation of MAPK, activates the PI3K/AKT/GSK-3β pathway, reduces GLRX expression, and regulates lipid metabolism. Ginsenoside F2 reduces ROS production and MDA levels, restores SOD activity in cells, and alleviates oxidative stress. Ginsenoside F2 induces cell apoptosis (Apoptosis) and increases the number of cleaved caspase-3-positive cells. Ginsenoside F2 reduces body weight gain, adipose tissue weight and serum lipid levels in obese mice, and activates the hepatic AMPK signaling pathway and the expression of antioxidant enzymes. Ginsenoside F2 alleviates atopic dermatitis in mice by inhibiting inflammation and reshaping the gut microbiota . Ginsenoside F2 is applicable to research related to insulin resistance, obesity, atopic dermatitis, liver cancer, glioblastoma and glioma .

HY-101036

Choline bitartrate 4 Publications Verification	Animals Ketones, Aldehydes, Acids Source Classification	mAChR Endogenous Metabolite
Choline bitartrate is a vitamin-like essential nutrient, can affect diseases such as liver disease, atherosclerosis and neurological disorders . Choline bitartrate is a precursor for the neurotransmitter acetylcholine, as a methyl donor in various metabolic processes, and in lipid metabolism .

HY-113081

1-Methyladenosine 4 Publications Verification	Alkaloids Microorganisms Immune System Disorder Classification of Application Fields Disease markers Other Diseases Endogenous metabolite Disease Research Fields Cancer Source Classification	Endogenous Metabolite PPAR Hedgehog
1-Methyladenosine is an RNA modification that can serve as a tumor marker, with elevated levels in the body associated with cancer development. Following 1-methyladenosine methylation, upregulation of PPARδ expression regulates cholesterol metabolism and activates Hedgehog signaling pathway, driving liver tumorigenesis .

HY-B0998

Dehydrocholic acid sodium Dehydrocholate sodium	Classification of Application Fields Other Diseases Endogenous metabolite Disease Research Fields Steroids Source Classification	Amylases Lipase Autophagy
Dehydrocholic acid (Dehydrocholate) sodium is an orally active hydrocholeretic agent. Dehydrocholic acid sodium modulates Autophagy, reduces serum amylase and lipase levels. Dehydrocholic acid sodium has the effects of promoting choleretic function, protecting the liver, reducing pancreatic damage, and regulating cholesterol metabolism. Dehydrocholic acid sodium can be used in the study of acute biliary pancreatitis and obstructive jaundice .

HY-113114

Tetrahydrocortisone	Structural Classification Classification of Application Fields Other Diseases Endogenous metabolite Disease Research Fields Steroids Source Classification	Endogenous Metabolite Glucocorticoid Receptor
Tetrahydrocortisone is a corticosteroid catalyzed from endogenous glucocorticoids by AKR1D1 (5_β-reductase). Its formation is mediated by AKR1D1 and regulated by the glucocorticoid receptor (GR). As one of the final products of glucocorticoid inactivation metabolism, Tetrahydrocortisone participates in the maintenance of glucocorticoid metabolic homeostasis in vivo. Tetrahydrocortisone can be used for mechanistic studies of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes, and also serves as a biomarker for in vivo AKR1D1 activity and glucocorticoid metabolic status .

HY-N2468

Xylobiose 1,4-β-D-Xylobiose; 1,4-D-Xylobiose	Zea mays L. Polysaccharides Classification of Application Fields Gramineae Other Diseases Plants Disease Research Fields Saccharides Source Classification	TNF Receptor Claudin HSP
Xylobiose (1,4-β-D-Xylobiose; 1,4-D-Xylobiose) is an orally active Claudin 2/CLDN2 inhibitor and HSP27 inducer. Xylobiose works by regulating intestinal barrier function and glucose and lipid metabolism-related signaling pathways. Xylobiose inhibits CLDN2 expression to reduce intestinal permeability, induces HSP27 to enhance cell protection, and regulates the miR-122a/miR-33a axis to inhibit liver lipid synthesis and improve insulin resistance. Xylobiose can strengthen intestinal barrier integrity, reduce blood sugar and blood lipid levels, and reduce oxidative stress and inflammatory response. Xylobiose can be used in the study of type 2 diabetes and metabolic syndrome .

HY-N0806

Sweroside 3 Publications Verification	Monophenols Classification of Application Fields Labiatae Lespedeza tomentosa (Thunb.) Siebold ex Maxim. Phenols Metabolic Disease Plants Disease Research Fields	Keap1-Nrf2 AMPK Sirtuin NF-κB NOD-like Receptor (NLR) Pyroptosis Apoptosis Autophagy PARP
Sweroside is an iridoid glycoside that targets multiple targets, including the Keap1/Nrf2 axis, NLRP3 inflammasome, SIRT1, NF-κB, AMPK/mTOR pathway, and caspase family. Sweroside promotes Nrf2 nuclear translocation by competitively binding to Keap1. Sweroside also inhibits oxidative stress and NLRP3-mediated pyroptosis by activating Nrf2, inhibits NF-κB inflammatory pathway by activating SIRT1, and promotes autophagy and induces caspase-dependent apoptosis via the AMPK/mTOR pathway. Sweroside has antioxidant, anti-inflammatory, anti-apoptotic, and lipid metabolism regulating activities, and can be used in the research of myocardial ischemia-reperfusion injury, leukemia, acute lung injury, non-alcoholic fatty liver disease, and other fields .

HY-N3021

D-chiro-Inositol	Natural Products Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite NF-κB TNF Receptor FOXO Microtubule/Tubulin
D-chiro-Inositol is a stereoisomer of inositol that exhibits activities such as improving glucose metabolism, anti-tumor effects, anti-inflammatory properties, and antioxidant activity. D-chiro-Inositol effectively alleviates cholestasis by enhancing bile acid secretion and reducing oxidative stress. D-chiro-Inositol improves insulin resistance, lowers hyperglycemia and circulating insulin levels, reduces serum androgen levels, and ameliorates some metabolic abnormalities associated with X syndrome by mimicking the action of insulin. Additionally, D-chiro-Inositol can induce a reduction in pro-inflammatory factors (such as Nf-κB) and cytokines (such as TNF-α), thereby exerting anti-inflammatory effects. D-chiro-Inositol may be used in the study of liver cirrhosis, breast cancer, type 2 diabetes, and polycystic ovary syndrome .

HY-N0712

Typhaneoside 3 Publications Verification	Cardiovascular Disease Flavonols Structural Classification Flavonoids Typhaceae Classification of Application Fields Typha angustifolia L. Phenols Polyphenols Plants Disease Research Fields Source Classification	Autophagy mTOR Akt FXR
Typhaneoside is an orally bioavailable signal modulator and cellular regulator. Typhaneoside regulates the PI3K/Akt/mTOR autophagy transduction pathway. Typhaneoside promotes the activation of AMP-activated protein kinase and Caspase-3, induces apoptosis, ferroptosis, autophagy, ROS accumulation, and cell cycle arrest at the G₂/M phase, and reduces cancer cell viability. Typhaneoside activates the farnesoid X receptor signaling pathway, improves glucose and lipid metabolism, alleviates inflammatory responses, oxidative stress and hepatic lipid accumulation, and exerts hepatoprotective effects. Typhaneoside is applicable to research related to post-myocardial infarction heart failure, acute myeloid leukemia, non-alcoholic fatty liver disease, and neurological disorders .

HY-W015608

2-Phenylpropionic acid	Immune System Disorder Classification of Application Fields Ketones, Aldehydes, Acids Disease markers Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
2-Phenylpropionic acid is an intermediate in the metabolism of alpha-Methylstyrene. 2-Phenylpropionic acid covalently binds to rat liver protein. 2-Phenylpropionic acid can be used in the research of nonsteroidal anti-inflammatory agents .

HY-N0546

Ligustroflavone 2 Publications Verification Nuezhenoside	Flavonoids Oleaceae Classification of Application Fields Flavones Ligustrum lucidum Ait. Phenols Polyphenols Metabolic Disease Plants Disease Research Fields Source Classification	CaSR RIP kinase Mixed Lineage Kinase TGF-beta/Smad
Ligustroflavone is an orally active flavonoid compound. Ligustroflavone can be extracted from Ligustrum lucidum. Ligustroflavone antagonizes the calcium-sensing receptor (CaSR), inhibits the RIPK1/RIPK3/MLKL pathway, and downregulates TGF-β/Smad signaling. Ligustroflavone regulates calcium metabolism, protects bone tissue, reduces cerebral ischemic injury, and inhibits liver fibrosis. Ligustroflavone can be used in the study of diabetic osteoporosis, ischemic stroke, and liver fibrosis .

HY-N2181

Acetylshikonin 3 Publications Verification	Quinones Classification of Application Fields Phenols Polyphenols Plants Lithospermum erythrorhizon Sieb. et Zucc. Naphthalene Quinones Boraginaceae Inflammation/Immunology Disease Research Fields Source Classification	Cytochrome P450 Apoptosis Bacterial Autophagy
Acetylshikonin is an oral active anti-cancer, anti-inflammatory, antioxidant, anti-fertility, antibacterial, and neuroprotective agent. Acetylshikonin is a inhibitor of acetylcholinase (AChE) (IC₅₀=34.6 μM) and nonselective cytochrome P450. Acetylshikonin can induce Apoptosis and Autophagy in cancer cells. Acetylshikonin regulates blood glucose, liver fat metabolism, and renal fibrosis, and is used in the study of diabetes, diabetic nephropathy (DN), obesity, and nonalcoholic fatty liver disease (NAFLD) .

HY-W018004

L-Homocitrulline	Structural Classification Immune System Disorder Classification of Application Fields Ketones, Aldehydes, Acids Disease markers Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Amino Acid Derivatives Endogenous Metabolite
L-Homocitrulline is a carbamoylated derivative amino acid and a structural analog of L-citrulline. L-Homocitrulline serves not only as an intermediate in polypeptide synthesis but also converts into a variety of cyclic derivatives under enzymatic or acidic conditions. The level of L-Homocitrulline is significantly elevated in the serum of patients with non-alcoholic fatty liver disease (NAFLD), with high diagnostic accuracy. L-Homocitrulline also exists in patients with related diseases such as hypercitrullinemia. L-Homocitrulline is a key biomarker for monitoring abnormal liver metabolism and is widely used in NAFLD research .

HY-N10319

Artepillin C	Ketones, Aldehydes, Acids Plants Compositae Artemisia capillaris Thunb. Source Classification	Epigenetic Reader Domain Necroptosis TRP Channel
Artepillin C is an orally active CREB/CRTC2 inhibitor and TRPA1 covalent agonist (EC₅₀=1.8 μM). Artepillin C inhibits CREB/CRTC2-mediated gene transcription and downregulates BMAL1 expression to regulate glucose and lipid metabolism. Artepillin C can also activate TRPA1 channels to induce spicy taste signals. Artepillin C can inhibit tumor cell proliferation, induce necroptosis, improve insulin resistance and inhibit liver lipid synthesis. Artepillin C can be used in the study of metabolic syndrome, tumor prevention and treatment, and inflammation .

HY-113256

Linoleyl carnitine	Structural Classification Natural Products Endogenous metabolite Source Classification	Carnitine Palmitoyltransferase (CPT) Endogenous Metabolite
Linoleyl carnitine is an acylcarnitine and metabolite. Linoleyl carnitine in the liver is negatively correlated with pantothenic acid and citric acid in serum. Linoleyl carnitine accumulates in mitochondrial CPT II deficiency .

HY-B1134

Imazalil 1 Publications Verification Enilconazole	Infection Structural Classification Natural Products other families Classification of Application Fields Plants Disease Research Fields Biological Pesticide Research Source Classification Agricultural Research	Environmental Pollutants Fungal Pregnane X Receptor (PXR)
Imazalil (Enilconazole) is a fungicide. Imazalil has oral activity and strongly activates mPXR but not mCAR in mouse liver. Imazalil is commonly used to protect various agricultural crops against fungal attack. Imazalil induces developmental abnormalities, gut microbiota dysbiosis, and hepatic metabolism disorder .

HY-N0385

Gomisin J 3 Publications Verification	Cardiovascular Disease Structural Classification Monophenols Classification of Application Fields Lignans Phenols Phenylpropanoids Plants Schisandraceae Schisandra chinensis (Turcz.) Baill. Disease Research Fields Source Classification	NO Synthase AMPK CaMK NF-κB Keap1-Nrf2
Gomisin J is a Schisandra chinensis-derived lignan that can inhibit multiple targets such as eNOS, AMPK (LKB1, CaMKIIβ), fetuin-A, NF-κB, Nrf2/HO-1, and can pass through the blood-brain barrier. Gomisin J increases NO bioavailability by activating eNOS, regulates lipid metabolism by activating the AMPK pathway, inhibits fetuin-A and NF-κB to exert anti-inflammatory effects, and activates Nrf2/HO-1 to enhance antioxidant capacity. Gomisin J has the activities of anti-hypertension, regulating liver lipid metabolism, and reducing cerebral ischemia-reperfusion injury, and can be used for research on hypertension, non-alcoholic fatty liver disease, cerebral ischemia-reperfusion injury, etc .

HY-N10549

Gigantol 1 Publications Verification	Structural Classification Classification of Application Fields Orchidaceae Other Diseases Phenols Polyphenols Glucosinolates Plants Disease Research Fields Dendrobium nobile Lindl.	Ferroptosis c-Myc Glutathione Peroxidase JNK Reactive Oxygen Species (ROS) GSK-3
Gigantol is an orally active bibenzyl compound. Gigantol targets MYC to promote its ubiquitin-proteasomal degradation and inhibit the growth of lung cancer cells. Gigantol exerts anti-lung cancer activity by inducing ferroptosis (Ferroptosis) via the SLC7A11-GPX4 axis. Gigantol restores the sensitivity of mcr-harboring multidrug-resistant bacteria to colistin. Gigantol ameliorates carbon tetrachloride-induced liver injury by inhibiting the activation of the JNK/cPLA2/12-LOX inflammatory pathway. Gigantol promotes cholesterol metabolism and progesterone biosynthesis in Leydig cells. Gigantol can be used in studies related to diseases such as lung cancer, multidrug-resistant Gram-negative bacterial infections, and acute liver injury .

HY-N2853

D-α-Tocopherylquinone α-Tocopherylquinone	Quinones Microorganisms Classification of Application Fields Benzene Quinones Disease Research Fields Source Classification Cancer	Reactive Oxygen Species (ROS)
D-α-Tocopherylquinone (α-Tocopherylquinone) is a quinone, can be isolated from Phaeodactylum tricornutum. D-α-Tocopherylquinone is an oxidation product of α-Tocopherol (vitamin E). D-α-Tocopherylquinone can act as an anticoagulant and as an antioxidant. D-α-Tocopherylquinone reduces cellular oxidative damage produced by oxidized lipids. D-α-Tocopherylquinone binds to a liver cytosolic protein with a molecular mass of about 40 kDa. D-α-Tocopherylquinone binds to glurathione-S-transferase (GST) and can be transported to the site of metabolism or excreted in the bile .

HY-114557

NSC 90469 3,5-Diiodo-L-thyronine	Structural Classification Monophenols Classification of Application Fields Ketones, Aldehydes, Acids Phenols Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	JNK NF-κB Sirtuin PGC-1α COX TGF-β Receptor Collagen
NSC 90469 (3,5-Diiodo-L-thyronine) is an orally active thyroid hormone derivative. NSC 90469 inhibits JNK phosphorylation and NF-κB acetylation, blocks SIRT1 protein expression, induces elevated PGC-1α levels, and stimulates COX activity. NSC 90469 enhances UCP1-mediated thermogenesis, increases hepatic Dio1 activity, inhibits TSH levels and hypothalamic-pituitary-thyroid axis function, enhances lipid metabolism, and regulates energy metabolism via the mitochondrial pathway. NSC 90469 prevents blood glucose reduction, reduces urinary albumin excretion, inhibits renal matrix expansion, decreases TGF-β1 expression, and reduces renal fibronectin and type Ⅳ collagen deposition. NSC 90469 also increases energy expenditure and prevents diet-induced overweight. NSC 90469 can be used in studies related to diabetic nephropathy, hypothyroidism, non-alcoholic fatty liver disease, and diet-induced obesity .

HY-N5132

(-)-Fenchone	Structural Classification Other Monoterpenes Classification of Application Fields Terpenoids Other Diseases Umbelliferae Plants Vernonia Schreb. Disease Research Fields Source Classification	Cytochrome P450
(-)-Fenchone is a bicyclic monoterpene and serves as a substrate for human liver microsomal cytochrome P450 enzymes CYP2A6 and CYP2B6. (-)-Fenchone is not metabolized by human CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4 enzymes. (-)-Fenchone undergoes hydroxylation to produce 6-exo-hydroxyfenchone, 6-endo-hydroxyfenchone, and 10-hydroxyfenchone. During the metabolism of (-)-Fenchone, CYP2A6 may play a more important role than CYP2B6 .

HY-113081R

1-Methyladenosine (Standard)	Alkaloids Structural Classification Microorganisms Immune System Disorder Disease markers Endogenous metabolite Cancer Source Classification	Reference Standards Endogenous Metabolite PPAR Hedgehog
1-Methyladenosine (Standard) is the analytical standard of 1-Methyladenosine. This product is intended for research and analytical applications. 1-Methyladenosine is an RNA modification that can serve as a tumor marker, with elevated levels in the body associated with cancer development. Following 1-methyladenosine methylation, upregulation of PPARδ expression regulates cholesterol metabolism and activates Hedgehog signaling pathway, driving liver tumorigenesis . In Vitro:Compared to surrounding tumor tissues, 1-methyladenosine methylation in RNA is aberrantly elevated in hepatocellular carcinoma (HCC) cell lines and liver cancer stem cells (CSCs). Methylated 1-methyladenosine can promote cholesterol synthesis and activate the Hedgehog signaling pathway by enhancing the translation of PPARδ in liver CSCs, ultimately driving the self-renewal and tumorigenesis of liver cancer stem cells .

HY-N4031

Humantenine	Alkaloids Structural Classification Classification of Application Fields Other Diseases Loganiaceae Plants Gelsemium eleganis (Gardn. et Champ.) Benth. Disease Research Fields Indole Alkaloids Source Classification	Anaplastic lymphoma kinase (ALK) METTL3
Humantenine is a highly toxic indole alkaloid from Gelsemium elegans (Gardn. & Champ.) Benth. that binds to RNA m6A modification regulatory proteins (ALKBH5, METTL). Humantenine stably binds via hydrogen bonding and hydrophobic interactions and disrupts the m6A methylation level of target genes, thereby impairing the expression of intestinal epithelial cell tight junction and cytoskeleton-related genes, causing intestinal barrier dysfunction and significant intestinal cytotoxicity. The intraperitoneal injection LD₅₀ values of Humantenine are <1 mg/kg in mice, 1.2 mg/kg in male rats and 1.5 mg/kg in female rats, respectively. Species differences exist in the metabolism of Humantenine in human, porcine, goat and rat liver microsomes, and demethylation, dehydrogenation and oxidation occur in liver microsomes .

HY-128421

Tridecanedioic acid Brassylic Acid	Classification of Application Fields Ketones, Aldehydes, Acids Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite Parasite
Tridecanedioic acid is an endogenous metabolite. Tridecanedioic acid is an endogenous metabolite. Tridecanedioic acid is related to the metabolic regulation of non-alcoholic fatty liver disease (NASH) and may be an important node molecule in the intestinal microbiota-host metabolism interaction network. Tridecanedioic acid is significantly accumulated in tolerant cabbage-type rapeseed varieties and has a lower content in sensitive varieties. It plays an important role in the defense response against the infection of the small cabbage moth (Plutella xylostella). Tridecanedioic acid can be used as a biomarker for plant insect resistance or a diagnostic marker for metabolic diseases .

HY-101036R

Choline bitartrate (Standard)	Structural Classification Animals Ketones, Aldehydes, Acids Source Classification	Reference Standards mAChR Endogenous Metabolite
Choline (bitartrate) (Standard) is the analytical standard of Choline (bitartrate). This product is intended for research and analytical applications. Choline bitartrate is a vitamin-like essential nutrient, can affect diseases such as liver disease, atherosclerosis and neurological disorders . Choline bitartrate is a precursor for the neurotransmitter acetylcholine, as a methyl donor in various metabolic processes, and in lipid metabolism .

HY-W024365

3-tert-Butyl-4-methoxyphenol	Monophenols Jatropha curcas Linn. Phenols Euphorbiaceae Plants Source Classification	PROTAC Linkers
3-tert-Butyl-4-methoxyphenol is a PROTAC linker, belongs to alkyl/ether class, with insecticidal activity. 3-tert-Butyl-4-methoxyphenol also induced increased activities of glutathione (GSH) S-transferase and epoxide hydrolase in the liver and forestomach tissues of A/HeJ mice, regulating the carcinogen metabolism system .

HY-N10319R

Artepillin C (Standard)	Ketones, Aldehydes, Acids Plants Compositae Artemisia capillaris Thunb. Source Classification	Reference Standards TRP Channel Necroptosis Epigenetic Reader Domain
Artepillin C (Standard) is the analytical standard of Artepillin C (HY-N10319). This product is intended for research and analytical applications. Artepillin C is an orally active CREB/CRTC2 inhibitor and TRPA1 covalent agonist (EC₅₀=1.8 μM). Artepillin C inhibits CREB/CRTC2-mediated gene transcription and downregulates BMAL1 expression to regulate glucose and lipid metabolism. Artepillin C can also activate TRPA1 channels to induce spicy taste signals. Artepillin C can inhibit tumor cell proliferation, induce apoptosis, improve insulin resistance and inhibit liver lipid synthesis. Artepillin C can be used in the study of metabolic syndrome, tumor prevention and treatment, and inflammation .

HY-N9363

Corymbiferin	other families Xanthones Classification of Application Fields Phenols Polyphenols Metabolic Disease Plants Disease Research Fields Source Classification	Others
Corymbiferin is one of active constituents, responsible for anti-diabetic properties. Corymbiferin improves antioxidant capacity and carbohydrate metabolism in diabetic rats, along with the improvement of histopathology of livers and pancreatic β cells .

HY-W740611

Trihydroxycoprostane	Structural Classification Endogenous metabolite Steroids Source Classification	Drug Intermediate
Trihydroxycoprostane (THCP) is a polyhydroxysterane compound with a 5β configuration. ITrihydroxycoprostane acts as a key intermediate in the biosynthesis of bile acids from cholesterol and also serves as an important sterol metabolite generated by host-gut microbiota interactions. Trihydroxycoprostane can be used for mechanistic studies of diseases such as non-alcoholic fatty liver disease, inflammatory bowel disease, and bile acid metabolism disorders .

HY-128421R

Tridecanedioic acid (Standard) Brassylic Acid (Standard)	Structural Classification Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite Parasite
Tridecanedioic acid (Standard) is the analytical standard of Tridecanedioic acid (HY-128421). This product is intended for research and analytical applications. Tridecanedioic acid is an endogenous metabolite. Tridecanedioic acid is an endogenous metabolite. Tridecanedioic acid is related to the metabolic regulation of non-alcoholic fatty liver disease (NASH) and may be an important node molecule in the intestinal microbiota-host metabolism interaction network. Tridecanedioic acid is significantly accumulated in tolerant cabbage-type rapeseed varieties and has a lower content in sensitive varieties. It plays an important role in the defense response against the infection of the small cabbage moth (Plutella xylostella). Tridecanedioic acid can be used as a biomarker for plant insect resistance or a diagnostic marker for metabolic diseases.

HY-N3021R

D-chiro-Inositol (Standard)	Structural Classification Natural Products Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite NF-κB TNF Receptor FOXO Microtubule/Tubulin
D-chiro-Inositol is a stereoisomer of inositol that exhibits activities such as improving glucose metabolism, anti-tumor effects, anti-inflammatory properties, and antioxidant activity. D-chiro-Inositol effectively alleviates cholestasis by enhancing bile acid secretion and reducing oxidative stress. D-chiro-Inositol improves insulin resistance, lowers hyperglycemia and circulating insulin levels, reduces serum androgen levels, and ameliorates some metabolic abnormalities associated with X syndrome by mimicking the action of insulin. Additionally, D-chiro-Inositol can induce a reduction in pro-inflammatory factors (such as Nf-κB) and cytokines (such as TNF-α), thereby exerting anti-inflammatory effects. D-chiro-Inositol may be used in the study of liver cirrhosis, breast cancer, type 2 diabetes, and polycystic ovary syndrome .

HY-N0546R

Ligustroflavone (Standard) Nuezhenoside (Standard)	Structural Classification Flavonoids Oleaceae Flavones Ligustrum lucidum Ait. Phenols Polyphenols Plants Source Classification	Reference Standards CaSR RIP kinase Mixed Lineage Kinase TGF-beta/Smad
Ligustroflavone (Standard) is the analytical standard of Ligustroflavone (HY-N0546). This product is intended for research and analytical applications. Ligustroflavone is an orally active flavonoid compound. Ligustroflavone can be extracted from Ligustrum lucidum. Ligustroflavone antagonizes the calcium-sensing receptor (CaSR), inhibits the RIPK1/RIPK3/MLKL pathway, and downregulates TGF-β/Smad signaling. Ligustroflavone regulates calcium metabolism, protects bone tissue, reduces cerebral ischemic injury, and inhibits liver fibrosis. Ligustroflavone can be used in the study of diabetic osteoporosis, ischemic stroke, and liver fibrosis .

HY-N7521

Procyanidin C2 Procyanidine C2	Structural Classification Polygonaceae Phenols Polyphenols Fagopyrum dibotrys (D. Don) Hara Plants Source Classification	Acetyl-CoA Carboxylase Fatty Acid Synthase (FASN) Stearoyl-CoA Desaturase (SCD) PPAR AMPK mTOR JNK
Procyanidin C2 (Procyanidine C2) is a lipid metabolism regulator and antioxidant with free radical scavenging activity. Procyanidin C2 down-regulates ACC, SREBP-1c, FAS, SCD-1 and PPARγ. Procyanidin C2 increases the level of phosphorylated AMPKα and inhibits the level of phosphorylated mTOR. Procyanidin C2 reduces lipid accumulation, alleviates oxidative stress, enhances fatty acid oxidation and improves mitochondrial function. Procyanidin C2 can be used in the research of non-alcoholic fatty liver disease .

HY-N2468R

Xylobiose (Standard) 1,4-β-D-Xylobiose (Standard); 1,4-D-Xylobiose (Standard)	Structural Classification Zea mays L. Polysaccharides Gramineae Plants Saccharides Source Classification	Reference Standards TNF Receptor Claudin HSP
Xylobiose (1,4-β-D-Xylobiose; 1,4-D-Xylobiose) is an orally active Claudin 2/CLDN2 inhibitor and HSP27 inducer. Xylobiose works by regulating intestinal barrier function and glucose and lipid metabolism-related signaling pathways. Xylobiose inhibits CLDN2 expression to reduce intestinal permeability, induces HSP27 to enhance cell protection, and regulates the miR-122a/miR-33a axis to inhibit liver lipid synthesis and improve insulin resistance. Xylobiose can strengthen intestinal barrier integrity, reduce blood sugar and blood lipid levels, and reduce oxidative stress and inflammatory response. Xylobiose can be used in the study of type 2 diabetes and metabolic syndrome .

HY-W015608R

2-Phenylpropionic acid (Standard)	Structural Classification Immune System Disorder Ketones, Aldehydes, Acids Disease markers Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite
2-Phenylpropionic acid (Standard) is the analytical standard of 2-Phenylpropionic acid (HY-W015608). This product is intended for research and analytical applications. 2-Phenylpropionic acid is an intermediate in the metabolism of alpha-Methylstyrene. 2-Phenylpropionic acid covalently binds to rat liver protein. 2-Phenylpropionic acid can be used in the research of nonsteroidal anti-inflammatory agents .

HY-B1134R

Imazalil (Standard) Enilconazole (Standard)	Structural Classification Natural Products other families Plants Source Classification	Reference Standards Fungal
Imazalil (Standard) is the analytical standard of Imazalil. This product is intended for research and analytical applications. Imazalil (Enilconazole) is a fungicide. Imazalil has oral activity and strongly activates mPXR but not mCAR in mouse liver. Imazalil is commonly used to protect various agricultural crops against fungal attack. Imazalil induces developmental abnormalities, gut microbiota dysbiosis, and hepatic metabolism disorder .

HY-113853

WF-10129	Microorganisms Ketones, Aldehydes, Acids Source Classification	Akt Apoptosis
WF-10129 is a cytotoxic steroidal compound isolated from the plant Physalis. WF-10129 inhibits liver cancer cell proliferation, induces apoptosis, interferes with metabolism, and significantly reduces lactate production in vitro and in vivo. WF-10129 can also exert anti-tumor activity by regulating the expression of related genes and proteins through the AKT-p53 pathway.

HY-N7860

Δ2-cis Eicosenoic acid	Animals Ketones, Aldehydes, Acids Source Classification	Others
Δ2-cis Eicosenoic acid is an α,β-unsaturated fatty acid that has been extracted from fresh water clams and purified. A related compound, 2-octadecenoic acid, has been shown to improve liver function and decrease blood sugar in streptozocin-induced diabetic rats. Δ2-cis Eicosenoic acid and its salts have potential medicinal use for treating diabetes and improving lipid metabolism.

HY-N11827

Isocorybulbine (+)-Isocorybulbine	Structural Classification Alkaloids Monophenols Phenols Plants Papaveraceae Alkaloid Dimers Corydalis turtschaninovii Bess. Source Classification	Drug Metabolite
Isocorybulbine ((+)-Isocorybulbine) is one of the main metabolites of Corydaline (HY-N0923) in human liver microsomes and liver cells. Corydaline has anti-acetylcholinesterase, anti-allergic, anti-allergic reaction and gastric emptying activities. Isocorybulbine can be used for the metabolic study of Corydaline .

HY-W024365R

3-tert-Butyl-4-methoxyphenol (Standard)	Monophenols Jatropha curcas Linn. Phenols Euphorbiaceae Plants Source Classification	PROTAC Linkers Reference Standards
3-tert-Butyl-4-methoxyphenol (Standard) is the analytical standard of 3-tert-Butyl-4-methoxyphenol. This product is intended for research and analytical applications. 3-tert-Butyl-4-methoxyphenol is a PROTAC linker, belongs to alkyl/ether class, with insecticidal activity. 3-tert-Butyl-4-methoxyphenol also induced increased activities of glutathione (GSH) S-transferase and epoxide hydrolase in the liver and forestomach tissues of A/HeJ mice, regulating the carcinogen metabolism system .

HY-N2853R

D-α-Tocopherylquinone (Standard) α-Tocopherylquinone (Standard)	Quinones Microorganisms Benzene Quinones Source Classification	Reference Standards Reactive Oxygen Species (ROS)
D-α-Tocopherylquinone (α-Tocopherylquinone) (Standard) is the analytical standard of D-α-Tocopherylquinone. This product is intended for research and analytical applications. D-α-Tocopherylquinone is a quinone, can be isolated from Phaeodactylum tricornutum. D-α-Tocopherylquinone is an oxidation product of α-Tocopherol (vitamin E). D-α-Tocopherylquinone can act as an anticoagulant and as an antioxidant. D-α-Tocopherylquinone reduces cellular oxidative damage produced by oxidized lipids. D-α-Tocopherylquinone binds to a liver cytosolic protein with a molecular mass of about 40 kDa. D-α-Tocopherylquinone binds to glurathione-S-transferase (GST) and can be transported to the site of metabolism or excreted in the bile .

HY-114557R

NSC 90469 (Standard) 3,5-Diiodo-L-thyronine (Standard)	Structural Classification Monophenols Ketones, Aldehydes, Acids Phenols Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite
NSC 90469 (Standard) is the analytical standard of NSC 90469. This product is intended for research and analytical applications. NSC 90469 (3,5-Diiodo-L-thyronine) is an orally active thyroid hormone derivative. NSC 90469 inhibits JNK phosphorylation and NF-κB acetylation, blocks SIRT1 protein expression, induces elevated PGC-1α levels, and stimulates COX activity. NSC 90469 enhances UCP1-mediated thermogenesis, increases hepatic Dio1 activity, inhibits TSH levels and hypothalamic-pituitary-thyroid axis function, enhances lipid metabolism, and regulates energy metabolism via the mitochondrial pathway. NSC 90469 prevents blood glucose reduction, reduces urinary albumin excretion, inhibits renal matrix expansion, decreases TGF-β1 expression, and reduces renal fibronectin and type Ⅳ collagen deposition. NSC 90469 also increases energy expenditure and prevents diet-induced overweight. NSC 90469 can be used in studies related to diabetic nephropathy, hypothyroidism, non-alcoholic fatty liver disease, and diet-induced obesity .

HY-N0806R

Sweroside (Standard)	Structural Classification Monophenols Labiatae Lespedeza tomentosa (Thunb.) Siebold ex Maxim. Phenols Plants	Reference Standards Keap1-Nrf2 AMPK Sirtuin NF-κB NOD-like Receptor (NLR) Pyroptosis Apoptosis Autophagy PARP
Sweroside (Standard) is the analytical standard of Sweroside (HY-N0806). This product is intended for research and analytical applications. Sweroside is an iridoid glycoside that targets multiple targets, including the Keap1/Nrf2 axis, NLRP3 inflammasome, SIRT1, NF-κB, AMPK/mTOR pathway, and caspase family. Sweroside promotes Nrf2 nuclear translocation by competitively binding to Keap1. Sweroside also inhibits oxidative stress and NLRP3-mediated pyroptosis by activating Nrf2, inhibits NF-κB inflammatory pathway by activating SIRT1, and promotes autophagy and induces caspase-dependent apoptosis via the AMPK/mTOR pathway. Sweroside has antioxidant, anti-inflammatory, anti-apoptotic, and lipid metabolism regulating activities, and can be used in the research of myocardial ischemia-reperfusion injury, leukemia, acute lung injury, non-alcoholic fatty liver disease, and other fields .

HY-N17773

Hydrangeic acid	Structural Classification Monophenols Hydrangeaceae Phenols Plants Source Classification	PPAR GLUT TNF Receptor
Hydrangeic acid is an orally effective stilbene-type glycolipid metabolism regulator that lowers blood glucose and lipids. It can be isolated from processed leaves of Hydrangea macrophylla var. thunbergii. Hydrangeic acid is associated with glycolipid metabolism and insulin sensitivity regulation. Hydrangeic acid does not directly activate PPARγ or PPARα, but instead upregulates the mRNA expression of adiponectin, PPARγ2, GLUT4, and fatty acid-binding protein aP2, and downregulates TNF-α mRNA expression, promoting adipogenesis, glucose uptake, and GLUT4 translocation in 3T3-L1 cells. Simultaneously, Hydrangeic acid inhibits inflammatory factor-induced NO production, exerting activity in improving insulin resistance. Hydrangeic acid can be used in research related to type 2 diabetes and does not cause liver weight gain as a side effect.

Cat. No.	Product Name	Chemical Structure

HY-114118S3

Semaglutide-13C6,15N TFA

Semaglutide- ¹³C₆, ¹⁵N TFA is the ¹³C- and ¹⁵N-labeled Semaglutide TFA (HY-114118A). Semaglutide TFA is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide TFA promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide TFA also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide TFA has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide TFA can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-114118S1

Semaglutide-d8 tetraTFA

Semaglutide-d₈ tetraTFA is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-114118S

Semaglutide-d8

Semaglutide-d₈ is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-113081S1

1-Methyladenosine-d3 hydriodide

1-Methyladenosine-d3 hydriodide is the deuterium labeled 1-Methyladenosine (HY-113081). 1-Methyladenosine is an RNA modification that can serve as a tumor marker, with elevated levels in the body associated with cancer development. Following 1-methyladenosine methylation, upregulation of PPARδ expression regulates cholesterol metabolism and activates Hedgehog signaling pathway, driving liver tumorigenesis .

HY-113081AS

1-Methyladenosine-d3 hydrochloride

1-Methyladenosine-d3 hydrochloride is the hydrochloride salt form of deuterium labeled 1-Methyladenosine (HY-113081). 1-Methyladenosine is an RNA modification that can serve as a tumor marker, with elevated levels in the body associated with cancer development. Following 1-methyladenosine methylation, upregulation of PPARδ expression regulates cholesterol metabolism and activates Hedgehog signaling pathway, driving liver tumorigenesis .

HY-113081S

1-Methyladenosine-d3
1-Methyl Adenosine-d3 is the deuterium labeled 1-Methyladenosine. 1-Methyladenosine is an RNA modification that can serve as a tumor marker, with elevated levels in the body associated with cancer development. Following 1-methyladenosine methylation, upregulation of PPARδ expression regulates cholesterol metabolism and activates Hedgehog signaling pathway, driving liver tumorigenesis .

HY-129491S

O-Desmethyl Midostaurin-d5
O-Desmethyl Midostaurin-d₅ is a deuterium labeled O-Desmethyl PKC412. O-Desmethyl Midostaurin (CGP62221; O-Desmethyl PKC412) is the active metabolite of Midostaurin (HY-10230) via cytochrome P450 liver enzyme metabolism .

HY-W751181

O-Desmethyl midostaurin-13C6

O-Desmethyl midostaurin- ¹³C₆ (CGP62221- ¹³C₆; O-Desmethyl PKC412- ¹³C₆) is the ¹³C-labeled O-Desmethyl Midostaurin (HY-129491). O-Desmethyl Midostaurin (CGP62221; O-Desmethyl PKC412) is the active metabolite of Midostaurin (HY-10230) via cytochrome P450 liver enzyme metabolism. O-Desmethyl Midostaurin can be used as an indicator for Midostaurin metabolism in vivo . Midostaurin is a multi-targeted protein kinase inhibitor?with?IC₅₀?ranging from 22-500 nM.

HY-B1858S

Isoprothiolane-d4

Isoprothiolane-d₄ is the deuterium labeled Isoprothiolane (HY-B1858). Isoprothiolane is a blast fungicide with antifungal, anti-inflammatory and insecticidal activities. Isoprothiolane primarily acts on fungi during the penetration and growth stages of infecting hyphae. Isoprothiolane can be used as an insecticide, pesticide, etc. In addition, Isoprothiolane can reduce serum phospholipid and total lipid concentrations, regulating lipid metabolism. Isoprothiolane is also used in the research of fatty liver .

HY-B1120S

Temephos-d12

Temephos-d₁₂ is the deuterium labeled Temephos. Temephos (Temefos) is an orally active, blood-brain barrier-permeable organophosphate insecticide and AChE inhibitor. By irreversibly inhibiting AChE to induce cholinergic overactivation, Temephos effectively blocks larval development of Aedes aegypti (yellow fever mosquito) and Aedes albopictus (Asian tiger mosquito), and is commonly used in studies related to Dengue Virus, Zika Virus and other relevant pathogens. Temephos exhibits genotoxicity and neurodevelopmental toxicity, and may also cause liver injury, reproductive system abnormalities and cholinergic poisoning symptoms in mammals. Temephos tends to accumulate in adipose tissues and aquatic organisms, and is excreted via feces after metabolism through oxidation and hydrolysis. Note that CYP-mediated metabolic detoxification may reduce the actual larvicidal efficacy of Temephos against some mosquito species. Temephos can be used in research related to dengue fever, Zika virus disease, chikungunya and dracunculiasis .

HY-W355700S

1-Oleoyl-2-hydroxy-sn-glycero-3-phosphoethanolamine-d31

1-Oleoyl-2-hydroxy-sn-glycero-3-phosphoethanolamine-d₃₁ is the deuterium labeled 1-Oleoyl-2-hydroxy-sn-glycero-3-phosphoethanolamine (HY-W355700). 1-oleoyl-sn-glycero-3-phosphoethanolamine (LysoPE 18:1) is a lysophosphatidylethanolamine molecule involved in phospholipid metabolism, targeting cell membrane receptors (such as G protein-coupled receptors) to regulate cell signaling pathways. 1-oleoyl-sn-glycero-3-phosphoethanolamine may activate mitogen-activated protein kinase (MAPK) signaling, promote cell migration, regulate inflammatory responses and lipid metabolism, and has both pro-inflammatory and anti-inflammatory activities. 1-oleoyl-sn-glycero-3-phosphoethanolamine is mainly used in the screening of biomarkers for metabolic diseases (such as non-alcoholic fatty liver disease and obesity), as well as the study of the mechanism of lysophospholipids in cell membrane homeostasis and signal transduction .

Cat. No.	Product Name		Classification

HY-W355700

1-Oleoyl-2-hydroxy-sn-glycero-3-phosphoethanolamine		Phospholipids
1-oleoyl-sn-glycero-3-phosphoethanolamine (LysoPE 18:1) is a lysophosphatidylethanolamine molecule involved in phospholipid metabolism, targeting cell membrane receptors (such as G protein-coupled receptors) to regulate cell signaling pathways. 1-oleoyl-sn-glycero-3-phosphoethanolamine may activate mitogen-activated protein kinase (MAPK) signaling, promote cell migration, regulate inflammatory responses and lipid metabolism, and has both pro-inflammatory and anti-inflammatory activities. 1-oleoyl-sn-glycero-3-phosphoethanolamine is mainly used in the screening of biomarkers for metabolic diseases (such as non-alcoholic fatty liver disease and obesity), as well as the study of the mechanism of lysophospholipids in cell membrane homeostasis and signal transduction .

HY-133971

Cholesterol 5α,6α-epoxide 5α,6α-Epoxycholesterol		Cholesterol
Cholesterol-5α,6α-epoxide is an epoxide derivative of cholesterol formed by the enzymatic oxidation of cholesterol in the liver and other tissues. Cholesterol-5α,6α-epoxide has unique chemical properties that make it an important intermediate in the biosynthesis of bile acids, which play a key role in the digestion and absorption of dietary fats. It also has a potential physiological role in regulating cholesterol metabolism and transport, although its biological function is not fully understood.

HY-B1393

Dehydrocholic acid Dehydrocholate		Cholesterol
Dehydrocholic acid (Dehydrocholate) is an orally active hydrocholeretic agent. Dehydrocholic acid modulates Autophagy, reduces serum amylase and lipase levels. Dehydrocholic acid has the effects of promoting choleretic function, protecting the liver, reducing pancreatic damage, and regulating cholesterol metabolism. Dehydrocholic acid can be used in the study of acute biliary pancreatitis and obstructive jaundice .

HY-159709

VL-422		Cationic Lipids
VL-422 is an ionizable cationic lipid. VL-422 delivers CRISPR complementary single-guide RNA (sgRNA) and Cas9 mRNA to enable in vitro and in vivo gene editing. LNPs containing VL-422 loaded with Cas9 mRNA and sgRNA targeting the ANGPTL3 gene induce the deletion of premature stop codons within the ANGPTL3 gene in the liver of cynomolgus monkeys. Loss-of-function of ANGPTL3 leads to decreased levels of LDL, HDL and cholesterol in plasma. The VL-422 delivery system can be used for the research of gene editing strategies targeting lipid metabolism diseases .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Liver Metabolism

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

NaturalProducts

Isotope-Labeled Compounds

Oligonucleotides

Natural
Products